MecamylamineNicotinic AntagonistsNicotineNicotinic AgonistsReceptors, NicotinicDihydro-beta-ErythroidineChickenpox VaccineChlorisondamineRotavirus VaccinesGanglionic BlockersAzocinesImmunization ScheduleDrug IndustryDimethylphenylpiperazinium IodidePempidineCholinergic AntagonistsHexamethonium CompoundsPapillomavirus VaccinesChickenpoxAconitineHerpes Zoster VaccineQuinolizinesGanglionic StimulantsAIDS VaccinesScopolamine HydrobromideHerpes ZosterAcetylcholinePentolinium TartrateMuscarinic AntagonistsCholinergic AgentsVaccines, AttenuatedAtropineHerpesvirus 3, HumanHexamethoniumDose-Response Relationship, Drugalpha7 Nicotinic Acetylcholine ReceptorRotavirus InfectionsPhysostigmineDecamethonium CompoundsBicyclo Compounds, HeterocyclicSubstance Withdrawal SyndromeTubocurarinePharmacologyParasympathomimeticsBungarotoxinsDouble-Blind MethodTobacco Use DisorderRats, Sprague-DawleyVaccinationNeostigmineCholinergic AgonistsAntibodies, ViralMethyltyrosinesSelf StimulationCarotid BodyStereoisomerismMuscarinic AgonistsOxotremorineReceptors, Muscarinic
Group1
- A large SAR study of mecamylamine and its analogs was reported by a group from Merck in 1962. (wikipedia.org)